Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar, A.W.S. Ritchie et al.|The Lancet|2015Cited by 2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D. James, Matthew R. Sydes, Johann S. de Bono et al.|New England Journal of Medicine|2017Cited by 1.8k
Comprehensive geriatric assessment (CGA) in men age 70 or over with localized prostate cancer.G.E.C. Osborne, Alistair Ring, Duncan C. Gilbert et al.|Journal of Clinical Oncology|2014Cited by 0